利用纳米药物递送系统诱导免疫原性细胞死亡以提高癌症免疫治疗。
Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy.
机构信息
State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China; School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China; School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China.
State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China; School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China.
出版信息
Curr Opin Biotechnol. 2020 Dec;66:36-43. doi: 10.1016/j.copbio.2020.06.007. Epub 2020 Jul 13.
Many anti-cancer therapies can induce or enhance the immunogenic cell death (ICD), a process that releases damage-associated molecular patterns (DAMPs) to prime antigen processing and presentation necessary for successful cancer immunotherapy. However, the clinical potential of these therapies, especially the chemotherapy, is limited by serious systemic side effects, because of their non-specific accumulation out of the tumors. Nanosized drug delivery systems (NDDSs) can improve the specificity of anti-cancer therapies, which enhance ICD in the tumor while alleviating toxicities. In this review, we summarize recent progress of ICD-inducing NDDSs with a focus on their enhanced safety and efficacy for cancer immunotherapy.
许多抗癌疗法可以诱导或增强免疫原性细胞死亡（ICD），这是一个释放损伤相关分子模式（DAMPs）以启动抗原加工和呈递的过程，这是成功的癌症免疫治疗所必需的。然而，这些疗法的临床潜力，特别是化疗，受到严重的全身副作用的限制，因为它们在肿瘤外的非特异性积累。纳米药物递送系统（NDDS）可以提高抗癌疗法的特异性，在增强肿瘤中 ICD 的同时减轻毒性。在这篇综述中，我们总结了最近在诱导 ICD 的 NDDS 方面的进展，重点是提高其在癌症免疫治疗中的安全性和疗效。
Zotero 插件